Allied Flow
Aseptic high-speed cell sorters for regenerative medicine.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
JPY49.4m | Seed | ||
| Total Funding | 000k | ||
Allied Flow Inc. is a Japanese biotechnology company specializing in the development, manufacturing, and sale of equipment for research and diagnostics based on flow cytometry technology. The firm was founded on January 15, 2016, by Masahiko Kanda, who serves as the CEO. Kanda holds a doctorate in electronic physical engineering from Osaka University and has an extensive background in the field, including establishing the basic technology for cell sorters during his tenure at Sumitomo Electric Industries and later leading the development of domestic cell sorters at Bay Bioscience Co., Ltd.
The company's mission is to create new value for society based on its long-cultivated flow cytometry technology, which analyzes, separates, and purifies cells individually at high speed. Allied Flow's flagship product is the "FENIX" series, a high-speed droplet cell sorter that enables sterile cell sorting for therapeutic use in regenerative medicine. A key feature of the FENIX system is its decontamination capability and the use of disposable, single-use parts for all cell-contacting components, which prevents cross-contamination between patient samples and ensures safety and stability. This technology addresses a critical need in cell therapy by enabling the purification of clinically effective cells in a sterile, high-speed manner.
Allied Flow operates on a business model that combines direct equipment sales with the recurring revenue from selling consumable parts. Its primary clients include universities, bio-venture companies, and pharmaceutical firms involved in cell therapy, stem cell research, and immunotherapy. The company has received funding through various means, including government subsidies and equity crowdfunding platforms like FUNDINNO and CF Angels, to advance its research and development. The company plans to focus on the domestic Japanese market initially, with future expansion plans for China, Taiwan, Europe, and the United States. It also aims to apply its core technology to other sectors, such as dairy farming and biomass.
Keywords: flow cytometry, cell sorter, regenerative medicine, cell therapy, biotechnology, aseptic cell sorting, FENIX cell sorter, Masahiko Kanda, droplet sorter, cell purification, immunotherapy research, stem cell research, diagnostic equipment, single-use components, medical devices, life sciences